Condition
Oral Chronic Graft vs Host Disease
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Clobetasol Oral Rinse
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 3 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Clobetasol Oral Rinse1
- Budesonide1
Active Sponsors
- Dr. Falk Pharma GmbH1
- National Cancer Institute (NCI)1
Top Investigators
University of Rochester Medical Center, Division of Oral Medicine, Eastman Institute for Oral Health
National Cancer Institute (NCI)